Search Results 271-280 of 17253 for hba1c

  1. Publications - Marcus Vinicius R. Pinto, M.D., M.S. - Mayo Clinic

    HbA1c variability and long-term glycemic control are linked to peripheral neuropathy in patients with type 1 diabetes. Diabetol Metab Syndr. 2020; 12:85 ...

  2. Study Of Safety And Efficacy Of Dapagliflozin + Metformin XR Versus Metformin XR In Participants With HR+, HER2-, Advanced Breast Cancer While On Treatment With Alpelisib And Fulvestrant - Mayo Clinic

    Participants with an established diagnosis of diabetes mellitus type I or participants with uncontrolled type II diabetes mellitus (FPG > 160 mg/dL and/or HbA1c ...

  3. Clinical Trial Enzyme Application Targeting Venous Leg Ulcers - Mayo Clinic

    HbA1c > 8.5% at screening. Significant hepatic impairment as defined by screening LFTs of AST and ALT > 3 times upper limit of normal (1 retest allowed) ...

  4. A Study of Diabetes-associated Epigenomic Signatures in Humans - Mayo Clinic

    The obectives of this study are to identify insulin resistance (IR)-specific chromatin signatures in mature adipocytes and myotubes, and to identify IR-specific ...

  5. Mayo Clinic

    Randall Richardsons experience at the Bariatric Center the whole Mayo Clinic supports you. Sections. Products and services.

  6. RLY-2608-201-Ph2 Study Of RLY-2608 In PROS And PIK3CA Driven Malformations - Mayo Clinic

    ... (HbA1c) ≥ 7.0%; History of hypersensitivity to PI3K inhibitors. Any of the following cardiac criteria: Mean resting corrected QT interval using Fridericia's ...

  7. Low hemoglobin count Causes - Mayo Clinic

    A low hemoglobin count is a commonly seen blood test result. Hemoglobin (Hb or Hgb) is a protein in red blood cells that carries oxygen throughout the body.

  8. A Study Of XmAb ®18087 In Subjects With NET And GIST - Mayo Clinic

    Poorly controlled diabetes mellitus as evidenced by an HbA1c level ≥ 10%, or significant diabetes-related dietary or therapeutic regimen changes within 12 ...

  9. TECTONIC CAD IVL IDE Study - Mayo Clinic

    Subject has uncontrolled diabetes defined as a HbA1c ≥10%. 16. Subject has an active systemic infection on the day of the index procedure with either fever ...

  10. A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibrosis - Mayo Clinic

    HbA1c >9% at Screening 14. Diabetes mellitus other than type 2 15. Current treatment with insulin 16. Treatment with PPAR-gamma agonists (thiazolidinediones ...